GILEAD SCIENCES SL

🇪🇸Spain

Country: 🇪🇸Spain

Ownership: -

Established: 1994-01-01

Employees: -

Market Cap: $95.8B

Website: http://www.gilead.com/about/worldwide-operations/europe/spain

Clinical Trials

Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed-Dose Combination (FDC) for 6 Weeks in Adults With Acute Genotype 1 or 4 Hepatitis C Virus (HCV) and Chronic Human Immunodeficiency Virus (HIV)-1 Co-Infection

Phase 2

Completed

Conditions: Hepatitis C Infection With HIV Co-Infection

Interventions: Drug: LDV/SOF

First Posted Date: 2015-05-29

Last Posted Date: 2018-11-16

Lead Sponsor: Gilead Sciences

Target Recruit Count: 26

Registration Number: NCT02457611

Study to Assess the Long-term Safety and Efficacy of Tirabrutinib in Adults With Relapsed/Refractory B-cell Malignancies

Phase 1

Completed

Conditions: Relapsed/Refractory B-cell Malignancies

Interventions: Drug: Tirabrutinib

First Posted Date: 2015-05-29

Last Posted Date: 2022-03-24

Lead Sponsor: Gilead Sciences

Target Recruit Count: 29

Registration Number: NCT02457559

Locations: 🇫🇷
Hopital Saint Eloi, Montpellier, France
🇫🇷
Centre Hospitalier Lyon Sud, Pierre Benite, France
🇬🇧
Leicester Royal Infirmary, Leicester, United Kingdom

and more 3 locations

Pharmacokinetics of Eleclazine in Adults With Normal and Impaired Renal Function

Phase 1

Completed

Conditions: Long QT Syndrome

Interventions: Drug: Eleclazine

First Posted Date: 2015-05-12

Last Posted Date: 2015-12-22

Lead Sponsor: Gilead Sciences

Target Recruit Count: 55

Registration Number: NCT02441829

Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Adults Receiving Ruxolitinib as Therapy for Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis With Progressive or Relapsed Disease

Phase 1

Terminated

Conditions: Myelofibrosis

Interventions: Drug: Idelalisib
Drug: Ruxolitinib

First Posted Date: 2015-05-06

Last Posted Date: 2020-09-16

Lead Sponsor: Gilead Sciences

Target Recruit Count: 10

Registration Number: NCT02436135

Locations: 🇺🇸
Stanford Hospital and Clinics, Stanford, California, United States
🇺🇸
University of Michigan Health System, Ann Arbor, Michigan, United States

Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination Tablet With Ribavirin for 12 Weeks in Treatment-naive Adults With Chronic HCV Genotype 3 Infection

Phase 2

Completed

Conditions: Hepatitis C Virus Infection

Interventions: Drug: LDV/SOF
Drug: RBV

First Posted Date: 2015-04-10

Last Posted Date: 2018-11-16

Lead Sponsor: Gilead Sciences

Target Recruit Count: 111

Registration Number: NCT02413593

Pharmacokinetics of Eleclazine in Adults With Normal and Impaired Hepatic Function

Phase 1

Completed

Conditions: Long QT Syndrome

Interventions: Drug: Eleclazine

First Posted Date: 2015-04-08

Last Posted Date: 2019-07-29

Lead Sponsor: Gilead Sciences

Target Recruit Count: 49

Registration Number: NCT02412098

Safety and Efficacy of Andecaliximab in Participants With Moderately to Severely Active Crohn's Disease

Phase 2

Terminated

Conditions: Crohn's Disease

Interventions: Drug: Andecaliximab
Drug: Placebo

First Posted Date: 2015-04-01

Last Posted Date: 2019-04-23

Lead Sponsor: Gilead Sciences

Target Recruit Count: 187

Registration Number: NCT02405442

Locations: 🇦🇺
Royal Adelaide Hospital, Adelaide, South Australia, Australia
🇺🇸
University of Miami, Miami, Florida, United States
🇺🇸
University of Washington Medical Center, Seattle, Washington, United States

and more 69 locations

Safety and Efficacy of Entospletinib With Vincristine and Dexamethasone in Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)

Phase 1

Terminated

Conditions: Acute Lymphoblastic Leukemia

Interventions: Drug: Entospletinib
Drug: Vincristine
Drug: Dexamethasone
Drug: CNS Prophylaxis

First Posted Date: 2015-03-31

Last Posted Date: 2020-01-02

Lead Sponsor: Gilead Sciences

Target Recruit Count: 30

Registration Number: NCT02404220

Locations: 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸
UCLA, Los Angeles, California, United States
🇩🇪
Medizinische Klinik und Poliklinik I, Wurzburg, Germany

and more 10 locations

Pharmacokinetics of Voxilaprevir in Adults With Normal Renal Function and Severe Renal Impairment

Phase 1

Completed

Conditions: HCV Infection

Interventions: Drug: Voxilaprevir

First Posted Date: 2015-03-30

Last Posted Date: 2020-03-20

Lead Sponsor: Gilead Sciences

Target Recruit Count: 20

Registration Number: NCT02402452

Locations: 🇩🇪
APEX GmbH, München, Germany
🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸
Texas Liver Institute, San Antonio, Texas, United States

and more 1 locations

Pharmacokinetics of Bictegravir in Adults With Normal and Impaired Renal Function

Phase 1

Completed

Conditions: HIV

Interventions: Drug: Bictegravir

First Posted Date: 2015-03-27

Last Posted Date: 2019-10-11

Lead Sponsor: Gilead Sciences

Target Recruit Count: 19

Registration Number: NCT02400307

Locations: 🇺🇸
Avail Clinical Research, DeLand, Florida, United States
🇺🇸
Clinical Pharmacology of Miami, Inc., Miami, Florida, United States
🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States

and more 4 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy